10 kHz SCS
DeviceSpinal cord stimulation programmed to a frequency of 10 kHz
Other names: Nevro HFX therapy programmed to a frequency of 10 kHz or high frequency, 10 kHz SCS
NCT Number: NCT05777317
The purpose of this post-market study is to evaluate changes in pain and neurological function with high frequency, 10 kHz spinal cord stimulation (SCS) therapy in patients with chronic, intractable lower limb pain associated with diabetic peripheral neuropathy, a condition known as painful diabetic neuropathy (PDN). This is a multi-center, prospective, randomized controlled study to evaluate improvement in pain and neurological function in PDN patients, with neurological function assessed via objective measures. Patients will be randomized to conventional medical management (CMM) or 10 kHz SCS plus CMM.
This study is active but is not currently recruiting participants.
Notify Me22 year and older
All sexes
Interventional
Not applicable
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Spinal cord stimulation programmed to a frequency of 10 kHz
Other names: Nevro HFX therapy programmed to a frequency of 10 kHz or high frequency, 10 kHz SCS
Conventional medical management alone
Time frame: 6 months
The lower limb pain responder rate is the proportion of subjects who are pain responders, where a responder is defined as having at least 50% reduction in average lower limb pain score from baseline as measured on a 10-cm Visual Analog Scale (VAS, where a higher score indicates greater pain.
Time frame: 6 months
The neurological improvement responder rate is the proportion of subjects who are neurological improvement responders, where a responder is defined as having a decrease of at least 3 points, excluding changes in foot pain under symptom scores, as assessed via the modified Toronto Clinical Neuropathy Score (mTCNS). The mTCNS assesses the severity of symptoms and sensory function loss associated with diabetic neuropathy. All symptom and sensory test scores are summed to provide a total mTCNS score for each assessment. The mTCNS has a maximum score of 33, where a higher score indicates greater neuropathy severity.
Time frame: 3 months
The lower limb pain responder rate is the proportion of subjects who are pain responders, where a responder is defined as having at least 50% reduction in average lower limb pain score from baseline as measured on a 10-cm Visual Analog Scale (VAS), where a higher score indicates greater pain.
Time frame: 6 months
Percent change in average lower limb pain intensity from baseline as measured on a 10-cm Visual Analog Scale (VAS), where a higher score indicates greater pain.
Time frame: 6 months
Percent change in Pain and Sleep Questionnaire Three-Item Index (PSQ-3) score from baseline. PSQ-3 is a three-item questionnaire to assess the impact of chronic pain on sleep. Each question is answered on a 10-cm Visual Analog Scale (VAS), and the final score is the average of the three responses. A higher score indicates greater impact of chronic pain on sleep.
Time frame: 6 months
Average change in EuroQol 5-dimension 5-level (EQ-5D-5L) index score from baseline. EQ-5D-5L measures the subject's health state as assessed in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with 5 levels. The scores on these five dimensions can be presented as a health profile or can be converted to a single number summary called the "index value." A higher index score indicates higher quality of life.
Time frame: 6 months
Average change in Neuropathy-Specific Quality of Life Questionnaire (NeuroQol) score from baseline. The NeuroQol measures a patient's perception of the impact diabetic peripheral neuropathy and foot ulcers on quality of life. Each question uses a 5-point Likert scale from 1 ("never") to 5 ("all the time") for frequency of symptoms. A higher NeuroQol value indicates greater impact of diabetic neuropathy on quality of life.
Time frame: 6 months
Average change in intraepidermal nerve fiber (IENF) density at the lower calf from baseline. IENF is a measure of small nerve fiber density in the skin, with a higher value indicating greater density of nerve fibers.
Time frame: 6 months
Average change in the modified Toronto Clinical Neuropathy Score (mTCNS) from baseline. The mTCNS assesses the severity of symptoms and sensory function loss associated with diabetic neuropathy. All symptom and sensory test scores are summed to provide a total mTCNS score for each assessment. The mTCNS has a maximum score of 33, where a higher score indicates greater severity of neuropathy.
Time frame: 6 months
Average change in hemoglobin A1c (HbA1c) from baseline for patients with type 2 diabetes and HbA1c >= 8.0% at enrollment
Time frame: 6 months
Average change in body weight from baseline for patients with type 2 diabetes
Nevro Corp
Industry
PDN-SENSORY: A Multi-Center Randomized Controlled Trial to Evaluate Pain and Neurological Function With 10 kHz SCS in Treatment of Painful Diabetic Neuropathy
Acronym: PDN-SENSORY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06495424
Diabetes Complications, Diabetes Mellitus
Wilmington, Delaware, United States
View Trial DetailsNCT03228420
Diabetes Complications, Diabetes Mellitus
Bradenton, Florida, United States
View Trial DetailsNCT05937984
Diabetes Complications, Diabetes Mellitus
Hamilton, Ontario, Canada
View Trial DetailsNCT04678895
Diabetes Complications, Diabetes Mellitus
Lebanon, New Hampshire, United States
View Trial Details